The Cancer Letter

CMS proposes policy to move away from hospital-based care. CMS announced it is scrapping Medicare’s list of 1,700 procedures that the program will only pay for in inpatient settings. This move is a reprise from the first Trump administration. cancerletter.com/cancer-policy/…

Speaking on The Cancer Letter Podcast, Evers (@UKMarkey) and Libutti (@slibutti, @RutgersCancer) shared overlapping concerns about the latest headlines coming from Washington—particularly the morale of junior faculty and the potential impact of Medicaid cuts.…

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out cancerletter.com/conversation-w…

.@DrRobWinn/@VCUMassey: If Medicaid gets massive cuts or goes away, where will these patients get care? cancerletter.com/conversation-w…

Oncologist biotech entrepreneur George Tidmarsh joins @US_FDA as @FDACDERDirector. His appointment came out of “proximity” to Makary and Bhattacharya. cancerletter.com/the-cancer-let…

“Mismatched” transplants now safe for blood cancer patients, @UVACancerCenter study shows cancerletter.com/clinical-round…

Libutti (@slibutti, @RutgersCancer): "We need to ride out what I’ve heard referred to as a tempest and keep reassuring our faculty that we’re going to get through this together.” cancerletter.com/podcastc/20250…

Christopher Panczner appointed CEO of New York Proton Center (@nyproton) cancerletter.com/in-brief/20250…

Targeted radiation shows lower neurological death rate in brain metastases from SCLC, according to a study led by investigators from @MassGenBrigham cancerletter.com/clinical-round…

Is oncology ready to move away from animal testing? NIH has announced it will stop issuing funding opportunities solely dedicated to animal models, but has not published any formal guidance related to the announcement. cancerletter.com/podcastc/20250…

Evers (@UKMarkey): “I had a really good opportunity to talk to our congressional leaders several weeks ago, and there’s such great bipartisan support that everybody is saying, ‘Don’t worry, we understand and we want to keep the momentum going.’” cancerletter.com/podcastc/20250…

A substantial percentage of patients experienced clinically significant visual acuity changes as a result of treatment with Blenrep, FDA said. cancerletter.com/regulatory-new…

Lynn Henry named associate director for COE at @UMRogelCancer cancerletter.com/in-brief/20250…

.@OSUCCC_James launches pancreatic cancer trial via telehealth This fully remote telehealth trial offers eligible pancreatic cancer patients across the U.S. access to a promising targeted therapy—without ever leaving their homes. cancerletter.com/clinical-round…

"Despite being one of the most important sources of data in oncology drug development, imaging in clinical trials is stubbornly opaque, clunky, and often wrong," writes @Yunu_Inc's Jeff Sorenson cancerletter.com/sponsored-arti…

Lung Cancer Research Foundation (@lcrf_org) announces $3.75 million in research funding opportunities cancerletter.com/funding-opport…

CMS publishes Medicare physician fee schedule proposal. The proposed rule would “increase quality care” for Medicare recipients while significantly reducing unnecessary spending, CMS said. cancerletter.com/cancer-policy/…

ODAC July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug. cancerletter.com/regulatory-new…

Braftovi combination receives approval in China for BRAFV600E-mutant metastatic colorectal cancer cancerletter.com/drugs-and-targ…

Enrollment begins in NCI’s Vanguard study focused on defining benefits of MCD tests NCI has initiated a pilot study to address the feasibility of using multi-cancer detection, or MCD, tests in future randomized controlled trials. cancerletter.com/clinical-round…